The global self-injection devices market size is expected to reach USD 10.8 billion by 2030, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 5.7% from 2022 to 2030. Increasing patient volume and rising prevalence of chronic diseases along with the high adoption of advanced drug delivery systems are factors estimated to surge the demand for self-injection devices.
Self-injection Devices Market Report Highlights
- Needle-free injectors segment held the largest market share in 2021 owing to the rising demand for needle-free injectors and increased health consciousness among individuals
- The disposable segment held a significant market share in 2021 due to the ease of use and the presence of a built-in glass syringe that reduces the necessity of manually loading the glass syringe, eventually making it more convenient for patients
- The cancer segment is anticipated to gain the highest market share during the forecast period due to the increasing prevalence of cancer all across the globe
- North America led the market in 2021 owing to the increasing demand for self-injection devices used for the treatment of several chronic diseases
- The Asia Pacific region is expected to expand at the fastest CAGR during the forecast period due to the rising incidence of autoimmune diseases and high prevalence of cancer across several countries in the region
Gain deeper insights on the market and receive your free copy with TOC now @: Self-injection Devices Market Report
The invention of self-injectable delivery devices such as pre-filled syringes, pen injectors, autoinjectors, and needle-free injectors has made the self-administration of drugs easier and more convenient for patients. The major benefits of this device are easy self-administration, improved patient compliance, reduced anxiety, and dosage accuracy. They can deliver drugs through subcutaneous or intramuscular route. Furthermore, intensive efforts have been made for exploring the different types of currently available self-injectors for the management of emergency and chronic diseases. Prevention of needlestick injury is a primary factor for healthcare professionals and companies to introduce self-injection devices such as autoinjectors. To avoid needlestick injuries to healthcare workers, the U.S., Europe, and other markets mandate the use of safety devices. Several auto-injectors provide the additional benefit of needlestick protection to healthcare professionals. It is expected that in the U.S. about 69,000 injuries can be prevented annually. Numerous auto-injectors have integral and passive safety features that eliminate or reduce the risk of injury.
Innovation in the field of New Drug Delivery Systems (NDDDS) has led to the rising demand for self-administered medications. The invention of novel injectable delivery devices such as pre-filled syringes, pen injectors, autoinjectors, and needle-free injectors has made the self-administration of drugs easier and more convenient for patients. The majority of biological drugs are delivered using injections, which include the threat of needlestick injuries. To minimize this issue, pharmaceutical firms are developing self-administered needle-free injectors and patient-friendly medication-device combination products.
The COVID-19 pandemic has altered expectations and perceptions of delivery settings and contributed to a rise in preference for self-administration medication. As this becomes the norm, several manufacturers are inclined to make the patient experience the vital component of drug delivery design. Significantly, the COVID-19 vaccines will increase the demand for injectable devices and the pandemic has also shown the benefit of self-use devices as well as connected devices. Post-pandemic there may be a rise in upcoming innovation in devices and pharma manufacturers will progressively collaborate to use self-injection devices in combination with other digital assets such as apps, phones, and personal computers. Eventually, this will bring the patient into far greater control of their care.
Self-injection Devices Market Insights By Demographics
North America dominated the market, due to sedentary lifestyle, high cost of treatments, increasing elderly population, and high recurrence rate of autoimmune disorders. Factors such as the rising prevalence of chronic and lifestyle-related diseases and the presence of sophisticated healthcare infrastructure are predicted to accelerate the market growth. Europe accounted for the second-highest share of the market based on revenue. The increasing prevalence of chronic diseases is expected to drive the adoption of self-injection devices among healthcare professionals. The region is expected to witness lucrative growth during the forecast period due to the presence of skilled professionals and well-established healthcare infrastructure. Asia Pacific is predicted to exhibit a significant CAGR. Large unmet needs with improving healthcare facilities and developing reimbursement policies, especially in countries such as China and India are the factors anticipated to aid the growth of this market.
Competitive Analysis By Major Companies
The key market players engage in vital business strategies such as joint ventures, strategic partnerships and collaborations, mergers & acquisitions, new product launches, and product innovation, to build their market positions alongside gaining popularity in the market. The market is competitive as key players are engaged in rigorous R&D activities to develop cost-effective and efficient self-injection devices. Some prominent players in the global self-injection devices market include:
- Ypsomed AG
- BD
- Gerresheimer AG
- Antares Pharma
- Haselmeier AG
- NuGen Medical Devices
- Owen Mumford Ltd
For Any Questions or Inquire please visit @: https://www.grandviewresearch.com/industry-analysis/self-injection-devices-market-report/request/rs5
Self-Injection Devices Market Segmentation
Grand View Research has segmented the global self-injection devices market based on product, usability, application, and region
- Self-injection Devices Product Outlook (Revenue, USD Million, 2017 – 2030)
- Self-injection Devices Usability Outlook (Revenue, USD Million, 2017 – 2030)
- Self-injection Devices Application Outlook (Revenue, USD Million, 2017 -2030)
- Self-injection Devices Regional Outlook (Revenue, USD Million, 2017 – 2030)
- List of Key Players in the Self-Injection Devices Market
Research Methodology
We employ a comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecasts possible. We utilize a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. Data is continuously filtered to ensure that only validated and authenticated sources are considered. In addition, data is also mined from a host of reports in our repository, as well as a number of reputed paid databases. Our market estimates and forecasts are derived through simulation models. A unique model is created and customized for each study. Gathered information for market dynamics, technology landscape, application development, and pricing trends are fed into the model and analyzed simultaneously.
For Customized reports or Special Pricing please visit @: https://www.grandviewresearch.com/special-pricing/452590/rfsp2
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S. based market research and consulting company is registered in California and headquartered in San Francisco. Comprising o ver 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Contact:
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll-Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com